Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study-Reference-Cited by-同舟云学术

Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study

Published:2015-12-15 Issue:8 Volume:57 Page:1823-1830
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Arcari Annalisa,Chiappella Annalisa,Spina Michele,Zanlari Luca,Bernuzzi Patrizia,Valenti Vanessa,Tani Monica,Marasca Roberto,Cabras Maria Giuseppina,Zambello Renato,Santagostino Alberto,Ilariucci Fiorella,Carli Giuseppe,Musto Pellegrino,Savini Paolo,Marino Dario,Ghio Francesco,Gentile Massimo,Cox Maria Christina,Vallisa Daniele

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.3109/10428194.2015.1106536

Reference31 articles.

1. The epidemiology of non-Hodgkin's lymphoma

2. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma

3. Relapsed/Refractory Diffuse Large B-Cell Lymphoma

4. Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. What to Do When Chimeric Antigen Receptor T Cells Are Not the Most Appropriate Option in Second-Line Diffuse Large B Cell Lymphoma: Current Treatment Options for Transplant-Ineligible Patients;EMJ Hematology;2023-08-01

2. New treatment options in elderly patients with Diffuse Large B-cell Lymphoma;Frontiers in Oncology;2023-07-03

3. Multidimensional Results and Reflections on CAR-T: The Italian Evidence;International Journal of Environmental Research and Public Health;2023-02-21

4. Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey;Annals of Hematology;2022-11-19

5. Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The FUSION NHL 001 trial;Cancer Reports;2022-07-19